Skip to content

Description of the Safety and Functionality of a Rectoscope (P201630551)

Description of the Safety and Functionality of a Rectoscope (P201630551) That Allows the Identification of the Distal Section Margin in Oncological Rectal Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04899726
Enrollment
15
Registered
2021-05-24
Start date
2020-07-14
Completion date
2022-09-30
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncological Rectal Surgery

Brief summary

Most patients with rectal cancer receive neoadjuvant therapy. This usually causes a decrease in tumor size. In approximately 20% of patients who receive neoadjuvant therapy, the tumor disappears completely (complete pathological response), showing as a scar on the rectal mucosa, not noticeable from the rectal serosa, from outside the rectum, difficulting the identification of the tumor location by the surgeon. Rectoscope (p201630551) allows the surgeon to view the illuminated rectum from the patient's abdomen, determining the appropriate point of section of the rectum.

Interventions

DEVICERectoscope (P201630551)

Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.

Sponsors

Instituto de Investigación Hospital Universitario La Paz
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Pilot Study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women over 18 years old. * Patients with rectal cancer (15 cm or less from the anal margin), whether or not they have received neoadjuvant treatment, in whom cancer surgery is to be performed through the anterior (abdominal) route, whether laparoscopic or not. * Patients who accept their participation in this study, after explaining the study details. * Patients who sign the informed consent.

Exclusion criteria

* Patients who are going to undergo an abdominoperineal amputation or transanal surgery for rectal cancer. * Patients who do not accept their participation in this study.

Design outcomes

Primary

MeasureTime frameDescription
Number of adverse events related to use of the device.at immediate postoperative periodSafety. Clavien-Dindo classification will be used.
Evaluation of functionalityat surgeryCategorical variable. 3 options: 1. the device has worked without problems 2. the device has worked, but with problems 3. the device could not carry out its function.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026